Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity–#8211;pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society for the Study of Obesity
2021-09-01
|
| Series: | Journal of Obesity & Metabolic Syndrome |
| Subjects: | |
| Online Access: | http://journaleditor.inforang.com/journal/view.html?doi=10.7570/jomes21033 |